Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Hunt For Gardasil Adverse Events: A Preview Of Emerging Social Media Challenges

This article was originally published in The Pink Sheet Daily

Executive Summary

Bachmann-based brouhaha over Merck's human papilloma virus vaccine underscores the liability risks that firms can face as possible risks for their products are discussed more widely.

You may also be interested in...

Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge

Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.

Gardasil Getting Pediatric Safety Review

Despite the political noise around the human papillomavirus vaccine, there do not seem to be major new pediatric safety concerns for the Pediatric Advisory Committee to discuss as it reviews Gardasil and 14 other products.

Firms Navigate Social Media Safely Following Loss Of Facebook Protection

The drug industry has options beyond disappearing from Facebook and missing the opportunities the influential networking site offers.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts